Cure Sickle Cell Initiative | Page 3

CDE Detailed Report

Disease: Sickle Cell Disease
Sub-Domain: Assessments and Examinations
CRF: Immune Function Form

128 results.

CDE ID	CDE Name	Variable Name	Definition	Short Description	Additional Notes (Question Text)	Permissible Values	Description	Data Type	Disease Specific Instructions	Disease Specific Reference	Population	Classification (e.g., Core)	Version Number	Version Date	CRF Name (CRF Module / Guideline)	Sub Domain Name	Domain Name	Size	Input Restrictions	Measurement Type	Source	Form Set	Form	Field
C57965	Laboratory procedure percent lymphocytes value	LabProcedurePrctLymphocytesVal	Value of percent lymphocytes.	Value of percent lymphocytes.	Lymphocytes: %			Numeric Values	Report findings prior to any first treatment of the primary disease for which the HSCT is being performed.		Adult;Pediatric	Supplemental	1.00	2018-01-22 11:03:02.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry
C60051	Systemic infection organism 2 code	SystemicInfectOrganism2Code	Code specifying the second organism pertaining to the subject/participant's systemic infection that was identified.	Code specifying the second organism pertaining to the subject/participant's systemic infection that was identified.	Systemic infection Second organism	121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509	Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified	Numeric Values	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections.	CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved.	Adult;Pediatric	Supplemental	1.00	2020-09-02 13:41:44.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	77
C59987	Lymphocyte absolute count	LymphocyteAbsoluteCt	Absolute count of lymphocytes in cells per microliter (cells per cubic millimeter).	Absolute count of lymphocytes in cells per microliter (cells per cubic millimeter).	Absolute lymphocyte count: cells / uL (cells / mm^3)			Numeric Values	Specify the following lymphocyte analyses performed prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-01 17:43:47.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry	cells per microliter (cells/uL, cells/mm^3)	CIBMTR	n/a	Form 2031 revision 2	28
C60019	Lymphocyte function anti CD3 status	LymphocyteFuncAntiCD3Status	Status of anti-CD3 lymphocyte function.	Status of anti-CD3 lymphocyte function.	Anti-CD3	Absent;Low;Normal;Not tested	< 10% of control;10-30% of control;> 30% of control;Not tested	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-02 13:19:00.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	45
C60030	Hepatitis prominent feature ID indicator	HepatitisPromFeatIDInd	Indicator of whether hepatitis was a prominent feature of the subject/participant's ID.	Indicator of whether hepatitis was a prominent feature of the subject/participant's ID.	If hepatitis was present, was it a prominent feature of ID?	No;Yes	No;Yes	Alphanumeric	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen.		Adult;Pediatric	Supplemental	1.00	2020-09-02 14:22:19.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	56
C59966	Hemoglobin not tested status	HemoglobinNotTestedStatus	Status indicating that the subject/participant's hemoglobin was not tested.	Status indicating that the subject/participant's hemoglobin was not tested.	Hemoglobin	Not tested	Not tested	Alphanumeric	Report findings prior to any first treatment of the primary disease for which the HSCT is being performed.		Adult;Pediatric	Supplemental	1.00	2020-09-01 13:50:15.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	14: Not tested
C60062	Clinical features any listed present indicator	ClinFeatrAnyListedPresentInd	Indicator of whether the subject/participant presented with any of the following clinical features between diagnosis and prior to the transplant preparative regimen: Autoimmune hemolytic anemia--Bone abnormalities--Edema--Eosinophilia--Failure to thrive--Growth hormone deficiency--Growth retardation--Hepatosplenomegaly--Hypoproteinemia--Lymphoproliferative disease--Maternal T-cell engraftment--Microcephaly--Neutropenia--Skin rash--Thrombocytopenia--Warts--Other features	Indicator of whether the subject/participant presented with any of the specified clinical features between diagnosis and prior to the transplant preparative regimen.	Did the recipient experience any of the following clinical features (between diagnosis and prior to the preparative regimen)?: Autoimmune hemolytic anemia--Bone abnormalities--Edema--Eosinophilia--Failure to thrive (weight < 5th percentile)--Growth hormone deficiency--Growth retardation (height < 5th percentile)--Hepatosplenomegaly--Hypoproteinemia--Lymphoproliferative disease--Maternal T-cell engraftment--Microcephaly--Neutropenia--Skin rash--Thrombocytopenia (< 100 x 10^9/L)--Warts--Other features	No;Yes	No;Yes	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-03 14:30:43.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	88
C59998	Lymphocyte CD20 measurement	LymphocyteCD20Measr	Measurement of CD20 lymphocytes (B lymphocyte cells).	Measurement of CD20 lymphocytes (B lymphocyte cells).	CD20 (B lymphocyte cells): % or value			Numeric Values	Specify the following lymphocyte analyses performed prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-02 09:33:19.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	32
C60041	Pneumonia infectious organism code other text	PneumoniaInfectOrganismCodeOTH	The free-text field related to 'Pneumonia infectious organism 1 code', 'Pneumonia infectious organism 2 code', or 'Pneumonia infectious organism 3 code', specifying other text.	The free-text field related to 'Pneumonia infectious organism 1 code', 'Pneumonia infectious organism 2 code', or 'Pneumonia infectious organism 3 code', specifying other text.	Pneumonia Specify other organism			Alphanumeric	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections.		Adult;Pediatric	Supplemental	1.00	2020-09-02 14:17:24.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers	255	Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	67
C59977	Immunoglobulin M not tested status	IgMNotTestedStatus	Status indicating that the subject/participant's immunoglobulin M (IgM) was not tested.	Status indicating that the subject/participant's immunoglobulin M (IgM) was not tested.	IgM:	Not tested	Not tested	Alphanumeric	Specify the following quantitative immunoglobulins measured prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-01 13:50:15.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	19: Not tested
C60073	Hypoproteinemia prominent indicator	HypoproteinemiaPromnntInd	Indicator of whether the hypoproteinemia the subject/participant presents with is a prominent clinical feature.	Indicator of whether the hypoproteinemia the subject/participant presents with is a prominent clinical feature.	If present, is hypoproteinemia prominent?	No;Yes	No;Yes	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-03 15:35:46.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	110
C60009	Antibody response assessment date	AntibodyResponseAssessDate	Date on which the subject/participant's antibody responses were assessed.	Date on which the subject/participant's antibody responses were assessed.	Date antibody responses were assessed: (date closest to diagnosis, before any IVIG)			Date or Date & Time			Adult;Pediatric	Supplemental	1.00	2020-09-02 10:32:15.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	36
C58397	Laboratory procedure percent eosinophils value	LabProcedurePrctEosinophlsVal	Value of percent eosinophils.	Value of percent eosinophils.	Eosinophils: %			Numeric Values	Report findings prior to any first treatment of the primary disease for which the HSCT is being performed.		Adult;Pediatric	Supplemental	1.00	2018-01-22 11:03:02.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry
C60052	Systemic infection organism 3 code	SystemicInfectOrganism3Code	Code specifying the third organism pertaining to the subject/participant's systemic infection that was identified.	Code specifying the third organism pertaining to the subject/participant's systemic infection that was identified.	Systemic infection Third organism	121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509	Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified	Numeric Values	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections.	CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved.	Adult;Pediatric	Supplemental	1.00	2020-09-02 13:41:44.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	78
C59988	Lymphocyte CD3 measurement type	LymphocyteCD3MeasurementTyp	Type of measurement of CD3 lymphocytes (T cells) represented by the recorded value.	Type of measurement of CD3 lymphocytes (T cells) represented by the recorded value.	CD3 (T cells): % or value	Value;Percent of total lymphocytes	Value;Percent of total lymphocytes	Alphanumeric	Specify the following lymphocyte analyses performed prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-01 17:52:17.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	29
C60020	Lymphocyte function Candida antigen status	LymphcytFncCandidaAntgnStat	Status of Candida antigen lymphocyte function.	Status of Candida antigen lymphocyte function.	Candida antigen	Absent;Low;Normal;Not tested	< 10% of control;10-30% of control;> 30% of control;Not tested	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-02 13:19:00.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	46
C60031	Meningitis encephalitis present indicator	MeningitsEncephalitsPresentInd	Indicator of whether meningitis or encephalitis is present in the subject/participant.	Indicator of whether meningitis or encephalitis is present in the subject/participant.	Meningitis / encephalitis Site of infection?	No;Yes	No;Yes	Alphanumeric	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen.		Adult;Pediatric	Supplemental	1.00	2020-09-02 13:38:10.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	57. Site of infection?
C59967	Transfusion red blood cell within 30 days test date status	TrnsfusRBCWin30DyTstDtStatus	Status indicating that the subject/participant received a transfusion of red blood cells (RBC) within 30 days of the pertinent test date.	Status indicating that the subject/participant received a transfusion of red blood cells (RBC) within 30 days of the pertinent test date.	Transfused RBC < 30 days from date of test	Transfused red blood cells < 30 days from date of test	Transfused red blood cells (RBC) < 30 days from date of test	Alphanumeric	Report findings prior to any first treatment of the primary disease for which the HSCT is being performed.		Adult;Pediatric	Supplemental	1.00	2020-09-01 14:15:25.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	14: transfused RBC
C60063	Clinical features present type	ClinFeatrPresentTyp	Type(s) of clinical features the subject/participant presented with.	Type(s) of clinical features the subject/participant presented with.	Specify clinical features: Feature present?	Warts;Other features;Thrombocytopenia;Skin rash;Neutropenia;Microcephaly;Maternal T-cell engraftment;Lymphoproliferative disease;Hypoproteinemia;Hepatosplenomegaly;Growth retardation;Growth hormone deficiency;Failure to thrive;Eosinophilia;Edema;Bone abnormalities;Autoimmune hemolytic anemia	Warts;Other features, specify;Thrombocytopenia (< 100 x 10^9/L);Skin rash;Neutropenia;Microcephaly;Maternal T-cell engraftment;Lymphoproliferative disease;Hypoproteinemia;Hepatosplenomegaly;Growth retardation (height < 5th percentile);Growth hormone deficiency;Failure to thrive (weight < 5th percentile);Eosinophilia;Edema;Bone abnormalities;Autoimmune hemolytic anemia	Alphanumeric	Select all clinical features that are presesnt.		Adult;Pediatric	Supplemental	1.00	2020-09-03 14:36:31.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Multiple Pre-Defined Values Selected		CIBMTR	n/a	Form 2031 revision 2	89, 91, 93, 95, 97, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125
C59999	Lymphocyte CD20 count unit of measure	LymphocyteCD20CountUOM	Unit of measure pertaining to the count of CD20 lymphocytes (B lymphocyte cells) being reported.	Unit of measure pertaining to the count of CD20 lymphocytes (B lymphocyte cells) being reported.	CD20 (B lymphocyte cells): Specify units	x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested	x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested	Alphanumeric	Specify the following lymphocyte analyses performed prior to any disease treatment		Adult;Pediatric	Supplemental	1.00	2020-09-02 09:41:46.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	32. Specify units
C60042	Pneumonia prominent feature ID indicator	PneumoniaPromFeatIDInd	Indicator of whether pneumonia was a prominent feature of the subject/participant's ID.	Indicator of whether pneumonia was a prominent feature of the subject/participant's ID.	If pneumonia was present, was it a prominent feature of ID?	No;Yes	No;Yes	Alphanumeric	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen.		Adult;Pediatric	Supplemental	1.00	2020-09-02 14:22:19.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	68
C59978	Immunoglobulin A before treatment value	IgABeforeTxVal	Value of the subject/participant's immunoglobulin A (IgA) measurement prior to any disease treatment.	Value of the subject/participant's immunoglobulin A (IgA) measurement prior to any disease treatment.	IgA:			Numeric Values	Specify the following quantitative immunoglobulins measured prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-01 15:47:39.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	20: Value
C60074	Lymphoproliferative disease prominent indicator	LymphoproliferativDzPromnntInd	Indicator of whether the lymphoproliferative disease the subject/participant presents with is a prominent clinical feature.	Indicator of whether the lymphoproliferative disease the subject/participant presents with is a prominent clinical feature.	If present, is lymphoproliferative disease prominent?	No;Yes	No;Yes	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-03 15:35:46.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	112
C60010	Antibody bacteriophage phi X-174 other neoantigen response status	AbdyBctphgPhiX174OthAgnRspStat	Status of the antibody response for bacteriophage phi X-174 or other neoantigen.	Status of the antibody response for bacteriophage phi X-174 or other neoantigen.	Bacteriophage phi X-174 or other neoantigen	Absent;Low;Normal;Not tested	Absent;Low;Normal;Not tested	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-02 10:36:04.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	37
C59957	Complete blood count date	CompleteBloodCountDate	Date on which the complete blood count test was performed.	Date on which the complete blood count test was performed.	Date CBC tested: (testing done within 6 weeks of diagnosis)			Date or Date & Time	Report findings prior to any first treatment of the primary disease for which the HSCT is being performed.		Adult;Pediatric	Supplemental	1.00	2020-09-01 13:30:18.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	9
C60053	Systemic infection organism code other text	SystemicInfectOrganismCodeOTH	The free-text field related to 'Systemic infection organism 1 code', 'Systemic infection organism 2 code', or 'Systemic infection organism 3 code', specifying other text.	The free-text field related to 'Systemic infection organism 1 code', 'Systemic infection organism 2 code', or 'Systemic infection organism 3 code', specifying other text.	Systemic infection Specify other organism			Alphanumeric	Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections.		Adult;Pediatric	Supplemental	1.00	2020-09-02 14:17:24.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers	255	Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	79
C59989	Lymphocyte CD3 measurement	LymphocyteCD3Measr	Measurement of CD3 lymphocytes (T cells).	Measurement of CD3 lymphocytes (T cells).	CD3 (T cells): % or value			Numeric Values	Specify the following lymphocyte analyses performed prior to any disease treatment:		Adult;Pediatric	Supplemental	1.00	2020-09-02 09:33:19.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Free-Form Entry		CIBMTR	n/a	Form 2031 revision 2	29
C60021	Lymphocyte function concavalin A status	LymphcytFncConcavalinAStat	Status of concavalin A (ConA) lymphocyte function.	Status of concavalin A (ConA) lymphocyte function.	Concavalin A (ConA)	Absent;Low;Normal;Not tested	< 10% of control;10-30% of control;> 30% of control;Not tested	Alphanumeric			Adult;Pediatric	Supplemental	1.00	2020-09-02 13:19:00.0	Immune Function Form	Assessments and Examinations	Laboratory Tests and Biospecimens/Biomarkers		Single Pre-Defined Value Selected		CIBMTR	n/a	Form 2031 revision 2	47

128 results.